# Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)

> **NCT01678963** · PHASE2 · COMPLETED · sponsor: **Ohr Pharmaceutical Inc.** · enrollment: 142 (actual)

## Conditions studied

- Neovascular Age Related Macular Degeneration

## Interventions

- **DRUG:** Squalamine lactate
- **DRUG:** Vehicle control

## Key facts

- **NCT ID:** NCT01678963
- **Lead sponsor:** Ohr Pharmaceutical Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2015-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01678963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01678963, "Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01678963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*